Shield Therapeutics: Accrufer progressing nicely, new finance put in place
Last updated: 21:44 03 Oct 2023 AEDT, First published: 02:39 04 Oct 2023 AEDT
|
Shield Therapeutics' Q2 results and commentary suggest the US commercialisation of Accrufer (ferric maltol), which is conducted in collaboration with Viatris, continues to go well. However, the company has trimmed back its prescription volume guidance by c15-20% and highlighted that a high level of heavily discounted prescriptions - which had been thought might have started to reduce by now - is continuing to depress the average net realised price per prescription. The commentary on Q3 performance confirms an upward trend in sales trajectory, with an inflexion point now clear after the joint marketing operation became effective in Q2. Shield has issued new guidance for prescription volume this year of 100-130K (from 125-160K previously) and made broadly similar changes to those of 2024 and 2025. The 2023 figure would suggest a Q4 sales volume of between 45-75k prescriptions (i.e. 60-160% sequential Q-on-Q growth). We view this as a refinement and note that even after this, the wide Q4 range highlights the fact that projections are still highly uncertain at this relatively early point in the commercialisation phase. The results were accompanied by US$6.1mln equity fundraising as well as a US$20mln debt facility, both now completed, which should provide further growth capital and allow it to recruit a market access team to address an issue that is currently depressing the net realised price per prescription. The cash position at the end of June was US$13,6mln (c£10.7mln). The funds raised in the placing and open offer were used to redeem the US$5.7mln convertible debt held by AOP Health. The pro forma cash position at the end of September can be estimated at cUS$9m. With the new debt facility providing an additional US$20m of headroom, Shield believes it has sufficient resources to fund operations until it reaches projected cash flow breakeven in 2025 (previously end of 2024). |
Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) and this website (the Site) on the terms set out in this disclaimer, together with all other terms and conditions, disclaimers and other notices displayed elsewhere on this Site.
It is important for you to know that:
(a) none of the Content is, or is intended to be, general or personal advice
(b) the principal purpose of the Content is to provide factual information only and to comment on news;
(c) the Content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including in respect of any particular security, portfolio of securities, transaction or investment strategy, and must not be relied upon by you as such;
(d) in providing you with the Content, we have not considered your objectives, financial situation or needs; and
(e) you should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
The Content contains data (including but not limited to prices, statistics and calculated information) obtained from a variety of third party sources (Third Party Data). The Company does not make any representation or warranty that any of the Content, including the Third Party Data, will be reliable, accurate or complete. The Company disclaims all responsibility and liability arising in any way from any errors or omissions in the Content, including the Third Party Data, including any loss you may incur in connection with any action or decision made by you in reliance upon the Content or Third Party Data.
In certain circumstances the Company, its related bodies corporate, or their affiliates, may have received, or be entitled to receive, financial or other consideration in connection with providing information about certain entities on the Site, which may include the above Content.
FOR OUR FULL DISCLAIMER CLICK HEREThis document is published by Proactive Research and its contents have not been approved as a financial promotion by Proactive Investors Limited or any other FCA authorised person. This communication is made on the basis of the 'journalist exemption' provide for in Article 20 of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and having regard to the FCA rules, and in particular PERG 8.12.
Where the note contains a ‘buy, sell, hold’ recommend, Proactive Investors Limited is authorised to provide investment advice as defined by Article 53 of the RAO
FOR OUR FULL DISCLAIMER CLICK HERE